Over a follow-up period of 6.2 years, 513 participants were diagnosed with dementia. 5 key findings →
Design: cohort study Participants: 513 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
A significant reduction in underdiagnosis of dementia was observed between the two periods, consistent across most countries. 4 key findings →
Participants: 10,402 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Compared to good olfaction, moderate olfaction (hazard ratio [HR]: 1.53, 95% confidence interval [CI]: 1.26 to 1.86), hyposmia (HR: 2.24, 95% CI: 1.81 to 2.78), and anosmia (HR: 3.47, 95% CI: 2.77 to 4.34) were all associated with higher dementia hazard; these associations were consistent across age, race, sex, and APOE ε4 groups. 5 key findings →
Participants: 4,470 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Index participants averaged 71.9 years, with > 50% lacking formal education. 5 key findings →
Design: longitudinal study Participants: 1,309 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Linear and logistic regression showed that childhood rural residence was associated with lower memory (standardized beta (β) = -1.68, 95% Confidence Interval (CI) [-2.39, -0.97]), executive function (β = -1.20, 95% CI [-1.84, -0.55]), and language fluency (β = -0.86, 95% CI [-1.64, -0.08]). 5 key findings →
Participants: 3,073 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aims to assess the burden of young-onset dementia worldwide, regionally, and nationally during 1990-2021. 5 key findings →
Participants: 100,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
52/100
Adjudicated AKI, which was largely mild and reversible, was independently associated with increased risk of probable dementia and the composite of probable dementia and MCI in older adults at high cardiovascular risk. 5 key findings →
Design: cohort study Participants: 270 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We conducted a retrospective cohort study using the National Health Insurance Database in South Korea. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
= 1661), 622 developed dementia within 5 years. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the whole population (N = 1,214,286) and the subpopulation (N = 88,565), 5 % had no risk factors, 12 % had only one, and 82 % had multiple. 4 key findings →
Design: cross-sectional Participants: 1,214,286 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Nun Study is an iconic longitudinal study of aging and dementia on a cohort of 678 Catholic nuns from the School Sisters of Notre Dame. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
52/100
The study included 212 patients, with a mean age of 82.27 years. 5 key findings →
Design: cohort study Participants: 212 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundWith increasing population longevity, Alzheimer's disease and dementia have become a health priority, and high-quality incidence estimates are needed. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 6378 papers published between 2014 and 2023 were analyzed. 5 key findings →
Participants: 6,378 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Random forest classifier and feature selection procedures were used to select digital biomarkers. 1 key finding →
Participants: 1,324 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
11 variables were critical in the training phase, including educational level, depression, insomnia, age, Body Mass Index (BMI), medication count, gender, stenting, systolic blood pressure (sbp), neurosis and rapid eye movement. 4 key findings →
Design: cross-sectional Participants: 2,379 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Social isolation and loneliness have emerged as significant and modifiable risk factors for dementia, especially in older adults. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 118,790 participants (average age 64.26 ± 9.95 years, 48% male), 16.7% developed dementia during an average follow-up of 7.3 ± 2.3 years. 5 key findings →
Participants: 118,790 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There were 7458 incident all-cause dementia cases (1636 VaD, 3376 AD) after 4,165,352 person-years of follow-up. 5 key findings →
Participants: 313,248 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Parkinson disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy are synucleinopathies, characterized by neuronal loss, gliosis and the abnormal deposition of α-synuclein in vulnerable areas of the nervous system. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 87,229 matched patients per cohort, GLP-1 RA use was associated with a significantly lower risk of overall dementia (adjusted HR (AHR) 0.90; 95% CI 0.85 to 0.95), Alzheimer's disease (AD) (AHR 0.88; 95% CI 0.83 to 0.94), and non-vascular dementias (non-VaDs) (AHR 0.75; 95% CI 0.70 to 0.81) compared with metformin. 5 key findings →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of 4930 participants, 2052 (41%) had MCI. 5 key findings →
Design: cross-sectional Participants: 4,930 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Lewy body diseases are common neurodegenerative diseases, including Parkinson's disease (PD) and dementia with Lewy bodies, which lead to both motor and non-motor symptoms. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Females with sporadic bvFTD showed worse compulsive behavior (p = 0.026) and language impairments (p = 0.024) compared to females with genetic bvFTD (n = 152). 5 key findings →
Participants: 152 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.028). AAS perception stratifies FTD syndromes and constitutes a "real-world audiogram" in these diseases. 1 key finding →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →